FOR IMMEDIATE RELEASE
November 16, 2020

Contact:
Dr. Sanna Fowler
Head of External Communications
Lonza Group Ltd
Tel +41 61 316 8929
sanna.fowler@lonza.com

Statement from Basel, Switzerland

Quote from Pierre-Alain Ruffieux, Chief Executive Officer, Lonza:
“We congratulate Moderna on this important milestone, which represents a significant scientific achievement and serves as a testament to Moderna’s commitment to controlling the COVID-19 pandemic.

“We are proud to support Moderna in the production of mRNA-1273. Our collaboration will allow for the manufacture of material equivalent to 400 million doses per year from Lonza’s facilities. Large-scale production began at our Portsmouth, US site at the end of September and we are on track to begin production at our Visp, Switzerland site before the end of the year.

“With positive interim results from both Moderna’s and Pfizer’s mRNA vaccine candidates, we are witnessing a major step forward in the evolution of vaccine technology, with the potential to change the way we manage infection and disease in the future.”

About Lonza
At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.

We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.

Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at www.lonza.com and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.

Categorized in: ,